BIOCARE INFUSION
ONCOLOGY & THERAPEUTICS

STELARA (USTEKINUMAB) ORDER SET

FAX: 470.922.3656 | **PHONE:** 470.377.6400

PATIENT INFORMATION:

Fax completed form, insurance information, and clinical documentation to 470.922.3656

Patient Name: _____ DOB: _____ Phone: _____

Patient Status: ☐ New to Therapy ☐ Continuing Therapy **Next Treatment Date:**

MEDICAL INFORMATION

Patient weight: _____ lbs. (required) Allergies: _____

THERAPY ORDER

Diagnosis: ☐ Plaque Psoriasis ☐ Psoriatic Arthritis **ICD-10 Code**: _____

Stelara (adult dosing):

☐ Patients weighing < 100kg (220 lbs.), 45mg subQ initially and 4 weeks later, followed by 45mg every 12 weeks x 1 year

☐ Patients weighing > 100kg (220 lbs.), 90mg subQ initially and 4 weeks later, followed by 90mg every 12 weeks x 1 year

☐ Other:_____

Diagnosis: ☐ Crohn's Disease ☐ Ulcerative Colitis **ICD-10 Code**: _____

Stelara (adult dosing):

Initial Infusion: ☐ ≤55kg (<121 lbs.) 260mg IV over 1 hour x 1 dose

☐ >55kg to 85kg (121 lbs. to 187 lbs.) 390mg IV over 1 hour x 1 dose

☐ >85kg (>187lbs.) 520mg IV over 1 hour x 1 dose

Maintenance: ☐ 90mg subQ 8 weeks after initial infusion and then refill every 8 weeks for 1 year for a total of 6 refills

Lab Orders: _____ **Lab Frequency:** _____

☐ Yearly TB QFT test (optional) Required labs to be drawn by: ☐ Biocare Infusion ☐ Referring Provider

Other orders: _____

Anaphylactic Reaction Orders:

- Epinephrine (based on patient weight)
  - >30kg (>66lbs): EpiPen 0.3mg or compounded syringe IM or subQ; may repeat in 5-10 minutes x1
  - 15-30kg (33-66lbs): EpiPen Jr. 0.15mg or compounded syringe IM or subQ; may repeat in 5-10 minutes x1
- Diphenhydramine: Administer 25-50mg orally OR IV (adult)
- Refer to physician order or institutional protocol for pediatric dosing

Flush orders: NS 1-20mL pre/post infusion PRN and Heparin 10U/mL or 100U/mL per protocol as indicated PRN

PROVIDER INFORMATION

By signing this form and utilizing our services, you are authorizing *Biocare Infusion,* and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies, and to select the preferred site of care for the patient

Provider Name: _____ Signature: Date: _____

Provider NPI: _____ Phone: _____ Fax: _____ Contact Person: _____

☐ Opt out of Biocare Infusion selecting site of care (if checked, please list site of care):

PREFERRED LOCATION

City: _____ State: _____ *View our locations here:*

BIOCARE INFUSION
ONCOLOGY & THERAPEUTICS

COMPREHENSIVE SUPPORT FOR STELARA (USTEKINUMAB) THERAPY

PATIENT INFORMATION:

Patient Name: _____ DOB: _____

REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL

☐ Include signed and completed order (MD/prescriber to complete page 1)

☐ Include patient demographic information and insurance information

☐ Include patient's medication list

☐ Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy

☐ Has the patient had a documented contraindication/intolerance or failed trial of a DMARD, NSAID, or conventional therapy (i.e., MTX, 6-MP)? ☐ Yes ☐ No
If yes, which drug(s)? _____

☐ Does the patient have a contraindication/intolerance or failed trial to at least one biologic (i.e., Humira, Otezla, Stelara, Cimzia)? ☐ Yes ☐ No
If yes, which drug(s)? _____

☐ If psoriasis diagnosis, percent of body surface (BSA) involved: _____

☐ If psoriasis diagnosis, Psoriasis Area and Severity Index (PASI) score: _____

☐ Include labs and/or test results to support diagnosis

☐ *If applicable* - Last known biological therapy: _____ and last date received: _____. If patient is switching to biologic therapies, please perform a wash-out period of _____ weeks prior to starting Stelara.

☐ Other medical necessity: _____

REQUIRED PRE-SCREENING

☐ **TB screening test completed within 12 months - attach results**
☐ **Positive** ☐ **Negative**

*If TB results are positive - please provide documentation of treatment or medical clearance, and a negative CXR (TB+)

Biocare Infusion will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (470) 922-3656 or call (470) 377-6400 for assistance